MapLight CEO sells 68,491 shares under 10b5-1 plan
MapLight Therapeutics, Inc. Chief Executive Officer Christopher A. Kroeger reported multiple open-market sales of Voting Common Stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
MapLight Therapeutics, Inc. Chief Executive Officer Christopher A. Kroeger reported multiple open-market sales of Voting Common Stock. Across several trades on May 7–11, 2026, he sold a total of 68,491 shares, according to the transaction summary.
The sales were executed at weighted average prices within reported ranges from about $27.11 to $30.90 per share, with detailed ranges provided for each trade. A footnote states these transactions were carried out under a Rule 10b5-1 trading plan adopted on December 29, 2025, indicating they were pre-arranged rather than timed discretionarily.
Insider Trade Summary 10b5-1
Net Seller: 68,491 shares
Net Sell
10 txns
Insider
Kroeger Christopher A.
Role
Chief Executive Officer
Sold
68,491 shs ($1.95M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Voting Common Stock | 342 | $27.57 | $9K |
| Sale | Voting Common Stock | 877 | $28.70 | $25K |
| Sale | Voting Common Stock | 6,871 | $30.04 | $206K |
| Sale | Voting Common Stock | 5,890 | $30.56 | $180K |
| Sale | Voting Common Stock | 29,624 | $27.48 | $814K |
| Sale | Voting Common Stock | 1,582 | $28.56 | $45K |
| Sale | Voting Common Stock | 3,205 | $29.20 | $94K |
| Sale | Voting Common Stock | 14,880 | $28.47 | $424K |
| Sale | Voting Common Stock | 5,220 | $29.15 | $152K |
| holding | Voting Common Stock | -- | -- | -- |
Holdings After Transaction:
Voting Common Stock — 1,512,329 shares (Direct);
Voting Common Stock — 101,190 shares (Indirect, See footnote)
Footnotes (11)
- F1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025.
- F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.885 to $28.8833 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.91 to $29.325 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.11 to $28.1099 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.11 to $29.09 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.12 to $29.49 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.26 to $28.08 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.30 to $29.183 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F9. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.305 to $30.3045 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F10. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.305 to $30.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F11. The shares are held by the C&M Kroeger Nominee Trust, of which the Reporting Person is co-trustee with his spouse and has voting and dispositive power.
Key Figures
Shares sold: 68,491 shares
May 11 sale price: $30.56 per share
Additional May 11 price: $30.04 per share
+4 more
7 metrics
Shares sold
68,491 shares
Total non-derivative sales May 7–11, 2026
May 11 sale price
$30.56 per share
One reported open-market sale transaction
Additional May 11 price
$30.04 per share
Another May 11 open-market sale
Lowest reported price range
$27.11–$28.1099
Weighted average range in one footnote
Highest reported price range
$30.305–$30.90
Weighted average range in another footnote
Indirectly held shares
101,190 shares
Held by C&M Kroeger Nominee Trust as of May 7, 2026
10b5-1 plan adoption date
December 29, 2025
Date CEO adopted trading plan referenced in footnote
Key Terms
Rule 10b5-1 trading plan, weighted average price, voting and dispositive power, Voting Common Stock, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions..."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
voting and dispositive power financial
"The shares are held by the C&M Kroeger Nominee Trust, of which the Reporting Person is co-trustee with his spouse and has voting and dispositive power."
Voting Common Stock financial
"security_title: "Voting Common Stock" in each non-derivative transaction entry"
open-market sale financial
"transaction_action: "open-market sale" and description: "Sale in open market or private transaction""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did MapLight Therapeutics (MPLT) report in this Form 4?
MapLight Therapeutics reported that CEO Christopher A. Kroeger sold 68,491 shares of Voting Common Stock. These were open-market sales spread over May 7–11, 2026, as detailed in multiple line items in the Form 4 transaction table and summary.
Was the MapLight Therapeutics (MPLT) CEO’s stock sale made under a Rule 10b5-1 plan?
Yes. A footnote explains that at least one reported transaction was made under a Rule 10b5-1 trading plan adopted on December 29, 2025. Such plans pre-schedule trades, indicating that timing of these sales was arranged in advance rather than made opportunistically.
Does the Form 4 show any indirect holdings for the MapLight Therapeutics (MPLT) CEO?
Yes. One entry lists 101,190 shares of Voting Common Stock held indirectly as of May 7, 2026. A footnote states these shares are held by the C&M Kroeger Nominee Trust, where the reporting person and spouse act as co-trustees with voting and dispositive power.
AI-generated analysis. How Rhea-AI works. Not financial advice.
